Desai PM, Brown J, Gill S, et al. - Researchers report the outcomes of this trial of romyelocel-L (a universal, allogeneic myeloid progenitor cell product) to decrease infection during induction chemotherapy for acute myeloid leukemia (AML). There were 163 de novo AML patients (age ≥ 55 years) undergoing induction chemotherapy who were randomly assigned on day 0 (d0), of whom 120 were evaluable. Patients were administered either romyelocel-L infusion on d9 with granulocyte colony-stimulating factor (G-CSF) initiating daily d14 (treatment group) or G-CSF daily alone on d14 (control) until absolute neutrophil count recovery to 500/µL. Findings revealed a decreased incidence of infections, antimicrobial use, and hospitalization among patients treated with romyelocel-L, this implies that romyelocel-L may afford a new choice to decrease infections in patients with AML receiving induction therapy.